Innospec Résultats passés
Passé contrôle des critères 4/6
Les bénéfices de Innospec ont diminué à un taux annuel moyen de -3.8%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en baisse à 4% par an. Les revenus ont augmenté de en à un taux moyen de 5.2% par an. Le rendement des capitaux propres de Innospec est 8.4% et ses marges nettes sont de 6.4%.
Informations clés
-3.83%
Taux de croissance des bénéfices
-4.02%
Taux de croissance du BPA
| Chemicals Croissance de l'industrie | 12.93% |
| Taux de croissance des recettes | 5.18% |
| Rendement des fonds propres | 8.42% |
| Marge nette | 6.38% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 17
IOSP: Share Repurchases And Dividend Increase Will Support Future Upside
Analysts have adjusted their price target on Innospec to $99.33, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes fine-tune rather than overhaul their prior view.Mise à jour du récit • May 01
IOSP: Higher Revenue Outlook And Stable Fair Value Will Support Future Upside
Analysts have adjusted their price target for Innospec to $99.33. This reflects updated views on the company's discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.Mise à jour du récit • Apr 17
IOSP: Stable Margins And Lower Discount Rate Will Support Future Upside
Analysts have maintained their price target for Innospec at $99.33, citing only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions rather than any change in their overall view of the shares. Valuation Changes Fair Value: Model fair value remains unchanged at $99.33 per share.Mise à jour du récit • Apr 01
IOSP: Refined Discount Rate And Stable Margins Will Support Upside Potential
Analysts have set their price target for Innospec at $99.33. The updated view reflects modest adjustments to the discount rate, long-run revenue growth, profit margin and future P/E assumptions, while the fair value estimate remains $99.33.Mise à jour du récit • Mar 18
IOSP: Stable Assumptions And Lower Discount Rate Will Support Rebound Upside Potential
Analysts have nudged their price target for Innospec slightly lower to about $99.33, reflecting small refinements to their discount rate, projected revenue growth, profit margin and future P/E assumptions rather than a major shift in the story. Valuation Changes Fair Value: Model estimate is unchanged at about $99.33 per share.Seeking Alpha • Mar 14
Innospec: Oilfield Services Bound For A Recovery
Summary Innospec is positioned as a likely beneficiary of energy shortages and rising oil prices, supplying vital chemicals for oil extraction and refining. IOSP trades at a 50% discount to sector P/E and EV/EBITDA multiples, despite a debt-free balance sheet and strong free cash flow generation. Operational catalysts include potential recovery in oilfield services, resolution of the Mexico crisis, and increased demand from geopolitical disruptions. I rate IOSP a strong buy due to its discounted valuation, share repurchase support, and expected oilfield recovery. Read the full article on Seeking AlphaMise à jour du récit • Mar 04
IOSP: Higher Assumed P/E Will Support Rebound Upside Potential
Narrative Update The updated analyst price target for Innospec is now $99.33. Analysts point to adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind this revised view.Mise à jour du récit • Feb 18
IOSP: Steady Assumptions Will Support Rebound Upside Potential
Analysts maintained their Innospec fair value estimate at approximately $99, making only minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that support their price targets. Valuation Changes Fair Value: Kept steady at around $99 per share, with no change in the underlying estimate.Mise à jour du récit • Feb 04
IOSP: New Product And Opportunistic M&A Upside To Support Rebound
Analysts have adjusted their price target on Innospec to US$93, citing the stock's recent underperformance, what they describe as bottoming earnings, and potential upside from new product offerings or opportunistic M&A as key reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts view the new US$93 target as reflecting what they see as a discount to the company’s value as a specialty chemicals maker, given its product mix and market positions.Article d’analyse • Feb 03
Estimating The Fair Value Of Innospec Inc. (NASDAQ:IOSP)
Key Insights Innospec's estimated fair value is US$76.10 based on 2 Stage Free Cash Flow to Equity Innospec's US$83.50...Mise à jour du récit • Jan 20
IOSP: New Offerings And Opportunistic M&A Will Drive Future Upside Potential
Analysts have raised their price target on Innospec to US$93, stating that they view the stock as undervalued with potential upside from new product offerings or opportunistic M&A as earnings stabilize. Analyst Commentary Bullish Takeaways Bullish analysts view Innospec as undervalued relative to its current earnings profile, which they see as not fully reflecting potential contributions from new products or deals.Mise à jour du récit • Jan 06
IOSP: New Offerings And Opportunistic M&A Will Support Future Upside
Analysts have raised their price target on Innospec to about US$99. This change is supported by views that the company remains undervalued, with potential upside from new product offerings or opportunistic M&A, and an earnings profile that they believe has begun to bottom.Mise à jour du récit • Dec 14
IOSP: Share Repurchases And Dividend Increases Will Drive Future Upside
Analysts have modestly raised their price target on Innospec to approximately $99 per share from about $93, citing the stock's recent underperformance, bottoming earnings, and potential upside from new products or opportunistic M&A as supporting reasons for a more favorable risk reward outlook. Analyst Commentary Recent commentary from bullish analysts underscores a constructive stance on Innospec, emphasizing a favorable balance between current valuation and prospective growth drivers.Mise à jour du récit • Nov 29
IOSP: Share Repurchase And Dividend Will Drive Upside From Recent Lows
Analysts have lowered Innospec's fair value estimate from $107.50 to $99.33 per share, citing recent stock underperformance and the view that, although potential growth from new offerings or acquisitions exists, near-term challenges temper risk-reward expectations. Analyst Commentary Recent commentary from market observers provides a nuanced view of Innospec's near-term and long-term prospects.Mise à jour du récit • Nov 15
IOSP: Share Repurchase And Dividend Moves Will Sustain Bullish Momentum
Analysts have reaffirmed Innospec’s fair value estimate at $107.50 per share. They cite stable market conditions and modest improvements in profitability as factors supporting their unchanged outlook.Mise à jour du récit • Nov 01
IOSP: Continued Share Buybacks And Expanding Partnerships Will Support Future Upside
Analysts have maintained their price target for Innospec at $107.50, reflecting stability in their outlook as modest adjustments to discount rates and minor refinements in growth and margin forecasts were incorporated into their valuation models. What's in the News Performance Chemicals business enters its second year of partnership with International Justice Mission.Mise à jour du récit • Oct 18
Sustainable Chemicals And Battery Chemistry Will Open Future Markets
Analysts have lowered their fair value estimate for Innospec from $115 to $107.50. They cite tempered expectations for revenue growth and profit margins as the reason for this adjustment.Article d’analyse • Oct 10
Innospec Inc.'s (NASDAQ:IOSP) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Innospec Inc.'s ( NASDAQ:IOSP ) price-to-sales (or "P/S") ratio of 1.1x right now seems...Article d’analyse • Sep 25
Innospec Inc. (NASDAQ:IOSP) Shares Could Be 33% Above Their Intrinsic Value Estimate
Key Insights Innospec's estimated fair value is US$59.10 based on 2 Stage Free Cash Flow to Equity Innospec's US$78.60...Article d’analyse • Aug 07
Innospec (NASDAQ:IOSP) Will Want To Turn Around Its Return Trends
NasdaqGS:IOSP 1 Year Share Price vs Fair Value Explore Innospec's Fair Values from the Community and select yours...Article d’analyse • Jul 02
Innospec Inc. (NASDAQ:IOSP) Investors Are Less Pessimistic Than Expected
There wouldn't be many who think Innospec Inc.'s ( NASDAQ:IOSP ) price-to-sales (or "P/S") ratio of 1.2x is worth a...Article d’analyse • May 12
Innospec (NASDAQ:IOSP) Is Increasing Its Dividend To $0.84
Innospec Inc.'s ( NASDAQ:IOSP ) dividend will be increasing from last year's payment of the same period to $0.84 on...Article d’analyse • May 03
Should You Think About Buying Innospec Inc. (NASDAQ:IOSP) Now?
Innospec Inc. ( NASDAQ:IOSP ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...Article d’analyse • Mar 31
Innospec Inc.'s (NASDAQ:IOSP) Intrinsic Value Is Potentially 26% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Innospec fair value estimate is US$70.78 Current share price...Seeking Alpha • Mar 07
Innospec Well-Placed To Navigate Uncertain Times
Summary Innospec generated solid Q4 results relative to comparable specialty chemical companies, including strong volume growth in Fuel Specialties and Performance Chemicals and healthy margins. The outlook for 2025 is shakier, but diesel fuel demand should remain positive and further high-grading of the Performance Chemicals portfolio can offset some risk of weaker consumer spending. Oilfield is a harder call, given the company's exposure to more volatile trends in Latin America and the frac market. Despite a challenging macroeconomic environment, I remain bullish on Innospec's long-term prospects, driven by underlying volume growth drivers in Fuel Specialties and Performance Chemicals and opportunities to build the portfolio. Innospec's shares look undervalued, with discounted cash flow and EV/EBITDA pointing to a double-digit long-term annualized return and a target price of $120. Read the full article on Seeking AlphaArticle d’analyse • Feb 20
Innospec Inc. (NASDAQ:IOSP) Not Flying Under The Radar
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Article d’analyse • Feb 04
Returns At Innospec (NASDAQ:IOSP) Appear To Be Weighed Down
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Article d’analyse • Jan 13
Is Now An Opportune Moment To Examine Innospec Inc. (NASDAQ:IOSP)?
While Innospec Inc. ( NASDAQ:IOSP ) might not have the largest market cap around , it saw significant share price...Article d’analyse • Nov 25
Do Innospec's (NASDAQ:IOSP) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • Nov 09
Innospec (NASDAQ:IOSP) Will Pay A Larger Dividend Than Last Year At $0.79
Innospec Inc. ( NASDAQ:IOSP ) has announced that it will be increasing its dividend from last year's comparable payment...Article d’analyse • Nov 08
Innospec Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Shareholders of Innospec Inc. ( NASDAQ:IOSP ) will be pleased this week, given that the stock price is up 11% to US$120...Article d’analyse • Nov 07
Pinning Down Innospec Inc.'s (NASDAQ:IOSP) P/E Is Difficult Right Now
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Article d’analyse • Oct 22
Returns On Capital At Innospec (NASDAQ:IOSP) Have Stalled
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...Article d’analyse • Sep 17
At US$110, Is Innospec Inc. (NASDAQ:IOSP) Worth Looking At Closely?
While Innospec Inc. ( NASDAQ:IOSP ) might not have the largest market cap around , it saw significant share price...
Nouveau récit • Sep 09
Fuel Specialties And Performance Chemicals Propel Robust Financial Growth
Innospec's strategic acquisitions and innovation in Performance Chemicals and Fuel Specialties suggest sustained growth and improved profitability.Seeking Alpha • Aug 19
Innospec Navigating Turbulent End-Markets And Specialty Chemical De-Rating Relatively Well
Summary Despite outperforming many larger rivals, Innospec's stock has seen volatility, including recent weakness that was likely driven by very weak Oilfield Services revenue. Innospec's Q2 showed strength in Fuel Specialties and Performance Chemicals but was dragged down by significant weaknesses in Oilfield Services. Innospec's diverse markets offer growth opportunities but also face macroeconomic uncertainties. Innospec's focus on "better for you" personal care chemicals is a key differentiator. Innospec continues to leverage M&A, like its acquisition of QGP Quimica, to enhance its growth prospects, and I expect additional deals to add targeted product/market exposure. While near-term macro challenges persist, Innospec's disciplined R&D approach and focus on high-margin products position it for long-term growth with potential high single-digit to low double-digit returns. Read the full article on Seeking AlphaArticle d’analyse • Aug 01
Estimating The Intrinsic Value Of Innospec Inc. (NASDAQ:IOSP)
Key Insights The projected fair value for Innospec is US$115 based on 2 Stage Free Cash Flow to Equity With US$131...Article d’analyse • Jul 15
Returns On Capital At Innospec (NASDAQ:IOSP) Have Hit The Brakes
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Article d’analyse • Jun 12
With EPS Growth And More, Innospec (NASDAQ:IOSP) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • May 14
Innospec (NASDAQ:IOSP) Is Increasing Its Dividend To $0.76
Innospec Inc. ( NASDAQ:IOSP ) has announced that it will be increasing its dividend from last year's comparable payment...Article d’analyse • May 08
Innospec Inc.'s (NASDAQ:IOSP) Share Price Could Signal Some Risk
Innospec Inc.'s ( NASDAQ:IOSP ) price-to-earnings (or "P/E") ratio of 22.3x might make it look like a sell right now...Article d’analyse • Apr 11
Innospec (NASDAQ:IOSP) Has More To Do To Multiply In Value Going Forward
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Article d’analyse • Mar 28
Is Innospec Inc. (NASDAQ:IOSP) Potentially Undervalued?
Innospec Inc. ( NASDAQ:IOSP ), might not be a large cap stock, but it saw a decent share price growth of 13% on the...Article d’analyse • Mar 15
Estimating The Fair Value Of Innospec Inc. (NASDAQ:IOSP)
Key Insights Innospec's estimated fair value is US$134 based on 2 Stage Free Cash Flow to Equity Current share price of...Article d’analyse • Feb 16
Here's Why We Think Innospec (NASDAQ:IOSP) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Innospec gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 1,790 | 114 | 295 | 52 |
| 31 Dec 25 | 1,778 | 117 | 285 | 51 |
| 30 Sep 25 | 1,789 | -1 | 301 | 46 |
| 30 Jun 25 | 1,791 | 19 | 292 | 46 |
| 31 Mar 25 | 1,786 | 27 | 279 | 55 |
| 31 Dec 24 | 1,845 | 36 | 298 | 57 |
| 30 Sep 24 | 1,873 | 144 | 322 | 51 |
| 30 Jun 24 | 1,894 | 150 | 341 | 49 |
| 31 Mar 24 | 1,939 | 147 | 375 | 45 |
| 31 Dec 23 | 1,949 | 139 | 374 | 49 |
| 30 Sep 23 | 1,965 | 127 | 376 | 41 |
| 30 Jun 23 | 2,014 | 126 | 389 | 40 |
| 31 Mar 23 | 2,001 | 130 | 367 | 39 |
| 31 Dec 22 | 1,964 | 133 | 356 | 39 |
| 30 Sep 22 | 1,866 | 131 | 329 | 40 |
| 30 Jun 22 | 1,729 | 116 | 304 | 40 |
| 31 Mar 22 | 1,616 | 106 | 283 | 39 |
| 31 Dec 21 | 1,483 | 93 | 262 | 37 |
| 30 Sep 21 | 1,381 | 92 | 247 | 34 |
| 30 Jun 21 | 1,270 | 81 | 230 | 32 |
| 31 Mar 21 | 1,160 | 19 | 231 | 31 |
| 31 Dec 20 | 1,193 | 29 | 237 | 31 |
| 30 Sep 20 | 1,273 | 37 | 242 | 33 |
| 30 Jun 20 | 1,380 | 55 | 259 | 35 |
| 31 Mar 20 | 1,497 | 117 | 266 | 35 |
| 31 Dec 19 | 1,513 | 112 | 274 | 35 |
| 30 Sep 19 | 1,518 | 102 | 271 | 35 |
| 30 Jun 19 | 1,509 | 92 | 265 | 34 |
| 31 Mar 19 | 1,505 | 92 | 260 | 34 |
| 31 Dec 18 | 1,477 | 85 | 255 | 33 |
| 30 Sep 18 | 1,436 | 60 | 256 | 33 |
| 30 Jun 18 | 1,405 | 63 | 254 | 33 |
| 31 Mar 18 | 1,373 | 67 | 250 | 32 |
| 31 Dec 17 | 1,307 | 62 | 240 | 31 |
| 30 Sep 17 | 1,191 | 89 | 233 | 30 |
| 30 Jun 17 | 1,064 | 77 | 229 | 28 |
| 31 Mar 17 | 966 | 80 | 221 | 26 |
| 31 Dec 16 | 883 | 81 | 210 | 25 |
| 30 Sep 16 | 892 | 91 | 208 | 26 |
| 30 Jun 16 | 940 | 115 | 205 | 26 |
| 31 Mar 16 | 955 | 121 | 202 | 26 |
| 31 Dec 15 | 1,012 | 120 | 207 | 25 |
| 30 Sep 15 | 1,057 | 116 | 199 | 24 |
| 30 Jun 15 | 1,031 | 101 | 188 | 24 |
Des revenus de qualité: IOSP a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de IOSP sont plus élevées que l'année dernière IOSP. (6.4%) sont plus élevées que l'année dernière (1.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de IOSP ont diminué de 3.8% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de IOSP au cours de l'année écoulée ( 323% ) dépasse sa moyenne sur 5 ans ( -3.8% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices IOSP au cours de l'année écoulée ( 323% ) a dépassé celle du secteur Chemicals 0.1%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de IOSP ( 8.4% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/31 02:07 |
| Cours de l'action en fin de journée | 2026/05/29 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Innospec Inc. est couverte par 7 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jonathan Tanwanteng | CJS Securities, Inc. |
| David Silver | Freedom Capital Markets |
| Sean Milligan | Johnson Rice & Company, L.L.C. |